Although the risk of thromboembolism after total hip arthroplasty continues beyond hospital discharge, the cost-effectiveness of extending prophylaxis beyond hospitalization is unclear. We compared the cost-effectiveness of an extended duration of antithrombotic prophylaxis following total hip arthroplasty, with use of low-molecular-weight heparin or warfarin administered for twenty-eight days beyond hospital discharge, in terms of incremental cost per quality-adjusted life year gained.
|Number of pages||10|
|Journal||The Journal of Bone and Joint Surgery (American)|
|Publication status||Published - Apr 2007|
- Arthroplasty, Replacement, Hip
- Cost-Benefit Analysis
- Heparin, Low-Molecular-Weight
- Time Factors